In conclusion, investigating aetiological and prognostic heterogeneity among IHC defined subtypes of breast cancer requires the incorporation of measures of Ki67 and other IHC markers in large‐scale collaborative molecular epidemiological studies. This evidence concerns the gene MKI67 and breast cancer.